Source Count: 14 | Weighted Score: 40 | Source Confidence: [4/5] | Primary Tier: 1 | Last Updated: April 19, 2026
Keywords: proteomics, mass spectrometry, protein expression, protein-protein interactions, post-translational modifications, two-dimensional gel electrophoresis, tandem mass spectrometry, biomarker discovery, phosphoproteomics, human proteome project
Category Tags: z5 modern genomics technologies
Cross-References: Z_4_23 — Memory: Molecular and Physical Basis · Z_5_09 — Single-Cell Genomics · X_3_08 — Cancer Research History

QUICK SUMMARY

Proteomics — the large-scale study of the complete protein complement (proteome) of a cell, tissue, or organism — emerged in the 1990s as the necessary counterpart to genomics. While the human genome contains ~20,000 protein-coding genes, the human proteome encompasses an estimated 80,000–400,000 distinct protein forms due to alternative splicing, post-translational modifications (phosphorylation, glycosylation, ubiquitination, acetylation), and protein processing. The term "proteome" was coined by Marc Wilkins (Macquarie University) in 1994. Modern proteomics relies primarily on mass spectrometry (MS), particularly liquid chromatography-tandem mass spectrometry (LC-MS/MS), which can identify and quantify thousands of proteins from a single sample. The Human Proteome Project (HPP), launched in 2010 by the Human Proteome Organization (HUPO), aims to characterize at least one protein product for each human gene. Key applications include biomarker discovery for disease diagnosis, drug target identification, understanding cellular signaling networks, and characterizing the molecular basis of disease at a depth impossible with genomics alone — because proteins, not genes, are the functional molecules of life.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

• KEY FINDING The term "proteome" was coined by Marc Wilkins in 1994 and published in 1996, defined as "the entire protein complement expressed by a genome, or by a cell or tissue type." This conceptual advance recognized that understanding biology requires characterizing proteins — their abundance, modifications, interactions, and dynamics — not just the genes that encode them (Wilkins et al., 1996).
• Two-dimensional gel electrophoresis (2-DE), introduced by Patrick O'Farrell in 1975, was the first method capable of separating thousands of proteins from a cell lysate simultaneously. Proteins are separated by isoelectric point in one dimension and molecular weight in the second, producing a characteristic "spot map." While largely superseded by MS-based methods for discovery proteomics, 2-DE remains used for specific applications.
• KEY FINDING Electrospray ionization (ESI, John Fenn, Nobel Prize 2002) and matrix-assisted laser desorption/ionization (MALDI, Koichi Tanaka, Nobel Prize 2002) enabled the mass spectrometric analysis of intact proteins and peptides — the technological breakthrough that made modern proteomics possible. The 2002 Nobel Prize in Chemistry was awarded for these methods.
• Shotgun proteomics (also called bottom-up proteomics): proteins are enzymatically digested into peptides, separated by liquid chromatography, and analyzed by tandem mass spectrometry (LC-MS/MS). Modern instruments can identify >10,000 proteins from a single human cell lysate in a few hours. Matthias Mann (Max Planck Institute of Biochemistry) has been a leading developer of shotgun proteomics workflows and computational analysis tools (Cox and Mann, 2008).
• Post-translational modifications (PTMs) vastly expand proteome complexity: phosphorylation alone modifies an estimated 70% of human proteins and regulates virtually all signaling pathways. Phosphoproteomics — MS-based global analysis of phosphorylation — has revealed thousands of phosphorylation events that are dysregulated in cancer, diabetes, and neurodegeneration (Olsen et al., 2006).

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

• The Human Proteome Project (HPP), launched by HUPO in 2010, reported in 2020 that high-confidence evidence (MS data, antibody validation, or both) now exists for protein products of ~90% of human protein-coding genes (~18,000 of ~20,000). However, ~2,000 "missing proteins" remain undetected — likely because they are expressed at very low levels, in restricted tissues or developmental stages, or under specific conditions (Omenn et al., 2020).
• Clinical proteomics for biomarker discovery has identified hundreds of candidate disease biomarkers, but the translation rate from discovery to clinical use is extremely low (<1%). The "biomarker pipeline problem" reflects the enormous challenge of validating candidates across diverse populations and clinical settings. The most successful proteomic biomarkers to date include serum amyloid A for inflammation and several cancer-associated protein panels.
• Single-cell proteomics — measuring protein expression in individual cells — is an emerging frontier. Nikolai Slavov (Northeastern University) developed SCoPE-MS (Single Cell ProtEomics by Mass Spectrometry), enabling quantification of >1,000 proteins per cell. This technology promises to reveal cell-to-cell heterogeneity invisible to bulk measurements (Budnik et al., 2018).
• Structural proteomics — determining the three-dimensional structures of all proteins in a proteome — has been transformed by AlphaFold (DeepMind, 2021), which predicted structures for virtually all known protein sequences with experimental-level accuracy. The AlphaFold Protein Structure Database now contains >200 million predicted structures.

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

• Whether the full complexity of the human proteome (including all splice variants, PTM combinations, and protein complexes) can ever be comprehensively characterized is uncertain. The combinatorial explosion of modification states may create a "dark proteome" that is effectively unmeasurable with current technology.
• The hypothesis that proteomic signatures could serve as a comprehensive "molecular fingerprint" for personalized medicine — predicting drug response, disease trajectory, and optimal treatment — is conceptually compelling but requires vast clinical datasets that do not yet exist.
• Whether ancient proteins (paleoproteomics) can be reliably recovered from archaeological specimens older than ~1 million years is debated. Collagen and osteocalcin fragments have been extracted from specimens up to ~3.8 million years old, but the limits of protein preservation in deep time are not well established.

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

• DEBUNKED Claims that proteomic analysis has been used to prove the authenticity of religious relics (e.g., blood on the Shroud of Turin) confuse the detection of generic blood proteins with the identification of a specific individual — mass spectrometry can identify blood but cannot identify whose blood it is without genomic data.
• The claim that a single blood test can detect all cancers via proteomic biomarkers overstates current capabilities. Multi-cancer early detection tests (e.g., Galleri) use cell-free DNA methylation, not proteomics, and have significant limitations in sensitivity and specificity.

Counter-Arguments & Criticisms

• Proteomics suffers from a "dynamic range problem": plasma protein concentrations span ~12 orders of magnitude (albumin at ~50 mg/mL vs. cytokines at pg/mL), making comprehensive detection challenging. Current MS instruments have a dynamic range of ~4–5 orders of magnitude, meaning low-abundance proteins are routinely missed.
• Reproducibility across laboratories remains a concern: different sample preparation protocols, instrument platforms, and data analysis pipelines can produce substantially different results from identical samples.
• The relationship between protein abundance and biological function is not straightforward: enzyme activity, protein localization, complex formation, and PTM states are often more biologically relevant than total abundance, but are harder to measure at scale.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Aebersold, Ruedi; Mann, Matthias | 2003 | "Mass Spectrometry-Based Proteomics" | Nature | ∅ | 422::198–207 | ∅ | ∅ | doi:10.1038/nature01511 | ∅ | ∅ | ∅
2. Budnik, Bogdan, Levy, Ezra, Harmange, Guillaume; Slavov, Nikolai | 2018 | "SCoPE-MS: Mass Spectrometry of Single Mammalian Cells Quantifies Proteome Heterogeneity During Cell Differentiation" | Genome Biology | ∅ | 19.1::161 | ∅ | ∅ | doi:10.1186/s13059-018-1547-5 | ∅ | ∅ | ∅
3. Cox, Jürgen; Mann, Matthias | 2008 | "MaxQuant Enables High Peptide Identification Rates, Individualized p.p.b.-Range Mass Accuracies and Proteome-Wide Protein Quantification" | Nature Biotechnology | ∅ | 26.12::1367–1372 | ∅ | ∅ | doi:10.1038/nbt.1511 | ∅ | ∅ | ∅
4. Fenn, John, Mann, Matthias, Meng, Chin Kai, Wong, Shek Fu; Whitehouse, Craig | 1989 | "Electrospray Ionization for Mass Spectrometry of Large Biomolecules" | Science | ∅ | 246.4926::64–71 | ∅ | ∅ | doi:10.1126/science.2675315 | ∅ | ∅ | ∅
5. Jumper, John, Evans, Richard, Pritzel, Alexander, et al | 2021 | "Highly Accurate Protein Structure Prediction with AlphaFold" | Nature | ∅ | 596::583–589 | ∅ | ∅ | doi:10.1038/s41586-021-03819-2 | ∅ | ∅ | ∅
6. Olsen, Jesper, Blagoev, Blagoy, Gnad, Florian, et al | 2006 | "Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks" | Cell | ∅ | 127.3::635–648 | ∅ | ∅ | doi:10.1016/j.cell.2006.09.026 | ∅ | ∅ | ∅
7. Omenn, Gilbert, Lane, Lydie, Overall, Christopher, et al | 2020 | "Progress Identifying and Analyzing the Human Proteome: 2020 Metrics from the HUPO Human Proteome Project" | Journal of Proteome Research | ∅ | 20.1::330–340 | ∅ | ∅ | doi:10.1021/acs.jproteome.0c00680 | ∅ | ∅ | ∅
8. Wilkins, Marc, Sanchez, Jean-Charles, Gooley, Andrew, et al | 1996 | "Progress with Proteome Projects: Why All Proteins Expressed by a Genome Should Be Identified and How to Do It" | Biotechnology and Genetic Engineering Reviews | ∅ | 13.1::19–50 | ∅ | ∅ | doi:10.1080/02648725.1996.10647923 | ∅ | ∅ | ∅
9. Larance, Mark; Lamond, Angus | 2015 | "Multidimensional Proteomics for Cell Biology" | Nature Reviews Molecular Cell Biology | ∅ | 16.5::269–280 | ∅ | ∅ | doi:10.1038/nrm3970 | ∅ | ∅ | ∅
10. Domon, Bruno; Aebersold, Ruedi | 2006 | "Mass Spectrometry and Protein Analysis" | Science | ∅ | 312.5771::212–217 | ∅ | ∅ | doi:10.1126/science.1124619 | ∅ | ∅ | ∅
11. Altelaar, A.F | 2013 | "Next-Generation Proteomics: Towards an Integrative View of Proteome Dynamics" | Nature Reviews Genetics | ∅ | 14.1::35–48 | Maarten, Munoz, Javier, and Heck, Albert | ∅ | doi:10.1038/nrg3356 | ∅ | ∅ | ∅
12. Cravatt, Benjamin, Simon, Gabriel; Yates, John | 2007 | "The Biological Impact of Mass-Spectrometry-Based Proteomics" | Nature | ∅ | 450::991–1000 | ∅ | ∅ | doi:10.1038/nature06525 | ∅ | ∅ | ∅
13. Aebersold, Ruedi; Mann, Matthias | 2016 | "Mass-Spectrometric Exploration of Proteome Structure and Function" | Nature | ∅ | 537::347–355 | ∅ | ∅ | doi:10.1038/nature19949 | ∅ | ∅ | ∅
14. Dettmer, Katja, Aronov, Pavel; Hammock, Bruce | 2007 | "Mass Spectrometry-Based Metabolomics" | Mass Spectrometry Reviews | ∅ | 26.1::51–78 | ∅ | ∅ | doi:10.1002/mas.20108 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: April 19, 2026